Every round on record, with the sources behind each and the investors on them.
A biotech developing re-dosable, all-RNA gene-insertion therapies, including in vivo CAR T, for cancer, autoimmune and severe genetic diseases
typewritertx.comCambridge, MassachusettsBiotechFounded 2022
7 sources · checked 1 time, last 10d ago
Sources agree on the $56 million Series A, announcement date, lead investors, and participating investors. Source 4 says the round was "co-led" while the company release says "led by"; the company release is preferred.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A | $56M | 2026-09-02 | AN Venture Partners, RA Capital Management | No recent discussion |
7 sources · checked 1 time, last 10d ago [ VERIFIED ] read against 5 of 7 sources Sources agree on the $56 million Series A, announcement date, lead investors, and participating investors. Source 4 says the round was "co-led" while the company release says "led by"; the company release is preferred. | ||||
Typewriter Therapeutics develops all-RNA, non-viral genetic medicines that insert full-length therapeutic genes into genomic safe-harbor sites for patients with cancer, autoimmune diseases, and severe genetic disorders.
Checked against 10 sources on Sep 24
Also named as backers in company research: Japan Agency for Medical Research and Development (AMED)
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Seed | $5 million | 2024-02-27 | RA Capital Management, AN Venture Partners | |